BioCryst Pharmaceuticals-Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?

BioCryst Pharmaceuticals (BCRX) closed the last trading session at $10.08, gaining 48.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of$ 16.25 indicates a 61.2% upside potential.The mean estimate comprises 12 short-term price targets with a standard deviation of $5.66. While the lowest estimate of$ 8 indicates a 20.6% decline from the current price level, the most optimistic analy ...